XLO

Xilio Therapeutics Inc · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website xiliotx.com
Employees(FY) 81
ISIN US98422T1007

Performance

+24.27%

+25.49%

+63.62%

+35.18%

+132.73%

YTD

+155.8%

Profile

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors. The company also develops cytokine programs, which comprises XTX202, a tumor-activated IL-2; and XTX301, an investigational tumor-activated, engineered IL-12 molecule. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.

Advanced Technical Analysis

Technical Analysis of XLO 2024-12-20

The stock exhibits a strong bullish sentiment with a Moving Average Score of 96, indicating robust upward momentum, while the Technical Score of 76 further supports this positive outlook. However, the Oscillators Score of 56 suggests a more neutral stance, indicating potential consolidation or a pause in the upward trend, which investors should ...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of XLO

Stock Rank

Recent News & Updates

2024-12-18 18:30
Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI(Globenewswire)
2024-12-15 18:30
Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer(Globenewswire)
2024-12-08 20:55
After Golden Cross, Xilio Therapeutics, Inc. (XLO)'s Technical Outlook is Bright(Yahoo Finance)
2024-12-03 03:30
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-11-06 20:15
Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors(Globenewswire)
2024-11-06 20:05
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results(Globenewswire)
2024-10-29 21:01
Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting(Globenewswire)
2024-10-03 21:05
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting(Globenewswire)
2024-10-02 04:15
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-08-28 04:01
Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference(Globenewswire)
2024-08-07 19:30
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results(Globenewswire)
2024-06-13 04:05
Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors(Globenewswire)
2024-05-28 18:05
Gilead and Cartography enter deal to develop cancer therapies(Yahoo Finance)
2024-05-14 01:54
XLO Stock Earnings: Xilio Therapeutics Misses EPS for Q1 2024(Investorplace)
2024-05-13 19:30
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results(Globenewswire)
2024-04-15 21:14
Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why(Zacks)
2024-04-01 10:53
XLO Stock Earnings: Xilio Therapeutics Beats EPS for Q4 2023(Investorplace)
2024-04-01 04:05
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results(Globenewswire)
2024-03-27 23:10
Why Is Xilio Therapeutics (XLO) Stock up 168% Today?(Investorplace)
2024-03-27 19:05
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing(Globenewswire)
2024-03-27 19:00
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program(Globenewswire)
2024-03-27 18:45
Gilead bets on Xilio cancer drug as biotech restructures(Yahoo Finance)
2024-02-28 03:01
Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference(Globenewswire)
2024-01-31 03:01
Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference(Globenewswire)
2024-01-07 18:30
Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies(Globenewswire)
2023-12-06 18:30
Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data(Globenewswire)
2023-11-09 03:01
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results(Globenewswire)
2023-11-03 00:00
Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors(Globenewswire)
2023-10-30 21:15
Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting(Globenewswire)
2023-09-27 05:02
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer s (SITC) 38th Annual Meeting(Globenewswire)

Page 1 of 3

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.